Spectra Optia® Apheresis System: current insights into clinical risks and benefits (original) (raw)
Related papers
EPRA International Journal of Multidisciplinary Research (IJMR)
The present study investigates to prepare single donor Plasma Apheresis product in the blood center with the help of Fresenius Cell Separator for use in patientwho require coagulation factors, covid patients, dengue patients etc. Apheresis is a medical procedure that involves removing whole blood from a donor or patient and separating the blood into individual components so that one particular component can be removed.Apheresis is a medical procedure that involves removing whole blood from a donor or patient and separating the blood into individual components so that one particular component can be removed. The remaining blood components then are re-infused back into the bloodstream of the patient or donor. Apheresis is also called pheresis or hemapheresis. The terminology used may also reflect the component of blood that is being removed, such as: • Plasma (plasmapheresis) • Platelets (plateletpheresis) • Leukocytes (leukapheresis or leukopheresis) • Lymphocytes (lymphopheresis or ...
Cellular contamination of plasma collected with various apheresis systems
Transfusion and Apheresis Science, 2001
Efforts to improve the purity of blood products have mainly focused on reducing white blood cell (WBC) levels in cellular blood products. Relatively little attention has been given to the cellular purity of plasma. We evaluated plasma units collected on six apheresis systems: Dideco Excel, Haemonetics-MCS+, Fresenius-AS-Tech 204, Baxter-Amicus, Gambro BCT COBE Spectra and Gambro BCT-Trima. Collected plasma volumes averaged 300-350 ml for the various systems. Plasma samples were analyzed for platelet (PLT) content (Technicon H3, Bayer) and residual WBC (Imagn 2000). Results are given below. Platelet levels were consistently low for MCS+, COBE Spectra and Trima (all <50 x 10(3) microl(-1)), and were highest with AS204. Residual WBC levels were relatively low in all systems except MCS+. Extremely low levels were observed in Trima plasma. All of the Trima and Spectra units contained <1 x 10(6) WBC per product. With Excel, AS-Tech 204 and Amicus, 1 to 2 units were found to have >1 x 10(6) WBC, while almost all units from MCS+ exceeded this limit. Different levels of plasma purity were obtained with different apheresis systems. The Gambro BCT COBE Spectra and Trima systems were found to achieve consistently low levels of both platelets and WBC.
Apheresis Technologies and Clinical Applications: The 2000 International Apheresis Registry
Therapeutic Apheresis, 2008
The developments in apheresis technologies and techniques and their clinical applications worldwide are technologically, sociologically, and economically motivated. In past apheresis surveys the statistics have highlighted both the differences by geographic region in clinical practice and in the types of technologies utilized. While a national view of apheresis is very important, an international view may be more representative overall of this therapeutic modality than national results that are highly dependent on the local economics and the available technologies. These regional differences have provided a basis for scientific and clinical assessment of these apheresis technologies and their clinical outcomes, and have impacted the marketing and business developments of new technologies worldwide. The results of the International Apheresis Registry for 2005 reporting from 22 centers on 5 continents are presented. The survey collected data exclusively via a secure internet website on 1133 patients for a total of 6501 treatments. Unlike our prior registries, information on stem cell infusions was gathered. Information gathered included patient demographics, medical history, treatment diagnoses, treatment specifics (type, methodology, access type, anticoagulants, drugs, and equipment usage), side-effects, clinical response, and payment provider. As in the prior International Apheresis Registries for 1983, 2000, and 2002 the survey results highlight the regional differences in apheresis usage and treatment methodologies, indicating that an international overview of apheresis may be more representative of the impact of this therapeutic modality.
Comparison of source plasma quality in three different apheresis protocols
Transfusion, 2012
and because these components have been routinely tested for infectious agents before freezing. Furthermore, it was also demonstrated that frozen PLTs have a higher in vivo efficacy than liquid-preserved PLTs due to their procoagulant state. 4 Usage of frozen RBCs has advantages as well. The necessary deglycerolization washing step considerably reduces the amount of detrimental substances such as WBCs, cytokines, and other biologically active substances in the RBC unit that can affect transfusion outcome. 4 However, frozen RBCs are more costly. A unit of frozen RBCs costs approximately twice the amount of a refrigerated stored RBC unit. In addition, thawing and washing of cryopreserved RBC units requires skilled personnel and takes up to approximately 90 to 120 minutes. Yet despite these disadvantages, stockpiling a frozen RBC inventory proved to be an effective and safe blood resource in combat casualty care.
Adverse events associated with apheresis procedures: Incidence and relative frequency
Asian Journal of Transfusion Science, 2013
Introduction: Apheresis procedures [Plateletpheresis, Plasmapheresis/ Therapeutic Plasma Exchange (TPE), & Peripheral Blood Stem Cell Collection (PBSC)] are usually well tolerated. Occasionally, Adverse Events (AEs) of variable severity may occur during or after the procedure. AEs that occur in Donors/Patients are divided into local reactions and systemic reactions. Materials and Methods: A total of 3,367 apheresis procedures were performed, out of which 3,120 were plateletpheresis procedures, and out of which 1,401 were on Baxter CS 3000 & 1,719 were on Haemonetics MCS+ cell separators. Rest of 247 TPE & PBSC procedures were done on Haemonetics MCS+ cell separators. Results: 90 AEs were reported in relation to the 3,367 procedures. Out of 90 AEs, 85 AEs (94%) were associated with plateletpheresis (n = 3,120) and 05 AEs (06%) with TPE & PBSC (n = 247). The rate of vascular injury (VI), Citrate reaction (CR), and Presyncopal/Syncopal (PS/S) in plateletpheresis was 1.6% (52/3,120), 0.96% (30/3,120), and 0.096% (03/3,120), respectively. The rate of CR in TPE and PBSC was 1.23% (02/162) and 2.3% (02/85), respectively. The rate of PS/S in PBSC was 1.17% (01/85). AEs for Plateletpheresis, TPE & PBSC were 2.7% (85/3,120), 1.23% (02/162), and 3.5% (03/85), respectively. VI, CR, and PS/S were mostly of mild intensity. Both cell separators were equally safe, when AEs associated with plateletpheresis were compared with each other; 2.8% on CS 3000 & 2.6% on MCS+. Conclusion: Apheresis procedures performed on cell separators are safe, with a low incidence of significant AEs. No significant difference was noted in AEs among the two cell separators studied.
Complications after therapeutic plasma exchange within 24 hours
Apheresis (plural aphereses; from the ancient Greek aphaire-sis, "a taking away") is a procedure in which whole blood is removed from the body and passed through an apparatus that separates out one (or more) particular blood constituent. It then returns the remainder of the constituents to the individual's circulation. Through the use of sophisticated automation, an apheresis procedure can be performed on either a blood donor or a patient. 1 Therapeutic apheresis is the treatment of diseases through removal or extracorporeal manipulation of blood components or specific blood substances. It is distinct from blood component collection by apheresis. The goal of therapeutic apheresis is to remove a pathologic element from blood or to modulate cellular function by ABSTRACT Background: By therapeutic apheresis is to remove a pathologic element from blood or to modulate cellular function. By this study we observed, complications after the therapeutic plasma exchange (TPE) within 24 hours with respect to patient's demographic profiles and procedural variations. Methods: One-year prospective observational study conducted by the